Rubicon Research is a finished-dose manufacturer based in India. It appears in 32 regulatory filings across 8 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, NPRA (MY) and HSA (SG). Its GMP standing is certified by US FDA, EMA and MFDS (Korea), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 20 March 2025 as NAI. Customs aggregates show $109.5M of exports covering 2,904 molecules to 9 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Satara, United Arab Emirates | Not on file |
| Satara, India | 3012953979 |
| THANE DISTRICT, India | Not on file |
| Thane, India | 3008252295 |
| Thane, India | 3006559899 |
| Dhar, India | 3016480976 |
1 further sites are on record.
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 11 | 2 |
| NPRA (MY) | 9 | None |
| HSA (SG) | 6 | None |
| JFDA (JO) | 2 | None |
| EDE (AE) | 1 | None |
| ARCSA (EC) | 1 | None |
| EMA | None | 2 |
| MFDS (Korea) | None | 2 |
| MHRA (UK) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $22.2M | 4 |
| 2025 | Not reported | $109.5M | 9 |
| 2024 | Not reported | $100.8M | 8 |
| 2023 | Not reported | $92.1M | 9 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Rubicon Research comes back tiered against every other supplier able to file there.
Start for free